Compare FWRD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | VTYX |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.5M | 990.9M |
| IPO Year | 1993 | 2021 |
| Metric | FWRD | VTYX |
|---|---|---|
| Price | $28.00 | $14.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $35.00 | $13.50 |
| AVG Volume (30 Days) | 468.7K | ★ 5.7M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,496,734,000.00 | N/A |
| Revenue This Year | $2.78 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.54 | N/A |
| 52 Week Low | $9.79 | $0.78 |
| 52 Week High | $35.47 | $25.00 |
| Indicator | FWRD | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 76.63 |
| Support Level | $26.42 | $7.08 |
| Resistance Level | $29.31 | $13.90 |
| Average True Range (ATR) | 1.11 | 0.32 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 60.84 | 84.32 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.